摘要
目的:分析依折麦布联合中低强度阿托伐他汀在经皮冠状动脉介入术(PCI)治疗冠心病患者中的临床疗效。方法:选择奉新县人民医院2020年6月—2023年5月接受PCI术治疗的110例冠心病患者,根据随机数字表法分为观察组和对照组,每组55例。对照组采用阿托伐他汀治疗,观察组在对照组基础上采用依折麦布治疗。两组均随访12个月。比较两组超敏C反应蛋白(hs-CRP)、血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及心功能参数[左心室舒张末期内径(LVEDD)和左室射血分数(LVEF)]及不良反应事件发生情况。结果:治疗12个月后观察组hs-CRP,TC,TG,LDL-C和LVEDD均低于对照组,且HDL-C,LVEF高于对照组,差异有统计学意义(P<0.05)。随访12个月,观察组不良事件发生情况优于对照组,差异有统计学意义(P<0.05)。结论:依折麦布联合中低强度阿托伐他汀可改善血脂水平和心功能,显著提高冠心病PCI治疗效果,同时可降低炎症因子水平及PCI术后不良事件的发生情况。
Objective:To observe the clinical efficacy of ezetimibe combined with medium-low intensity atorvastatin in patients with coronary heart disease treated by percutaneous coronary intervention(PCI).Methods:All 110 patients with coronary heart disease who underwent PCI were divided into 2 groups according to random number table method,with 55 cases in each group.The control group was treated with atorvastatin while the observation group with ezetimibe on the basis of the control group.After 12 months of follow-up,the high-sensitivity C-reactive protein(hs-CRP),serum total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C),cardiac function parameters[left ventricular end-diastolic diameter(LVEDD)and left ventricular ejection fraction(LVEF)]and the occurrence of adverse events were compared between the two groups Results:After 12 months of treatment,the levels of TC,TG,LDL-C,hsCRP and LVEDD in the observation group were lower than those in the control group,and the levels of HDL-C and LVEF were higher than those in the control group(P<0.05).The rates of acute myocardial infarction,angina pectoris,stent restenosis and new coronary artery disease in observation group were lower than those in control group,and the difference was statistically significant(P<0.05).Conclusion:Ezetimibe combined with medium-low intensity atorvastatin can effectively reduce the levels of blood lipids and inflammatory factors in patients with coronary heart disease,improve the cardiac function of patients,and reduce the incidence of coronary artery disease and adverse events.
作者
邹鹏
李子良
钟顺波
ZOU Peng;LI Ziliang;ZHONG Shunbo(Fengxin People's Hospital,Fengxin 330700,China)
出处
《临床医药实践》
2025年第6期425-428,共4页
Proceeding of Clinical Medicine
关键词
依折麦布
阿托伐他汀
经皮冠状动脉介入术
冠心病
左室射血分数
ezetimibe
atorvastatin
percutaneous coronary intervention
coronary heart disease
left ventricular ejection fraction
